Altre lingue BioLineRx Ltd. Nasdaq

Azioni

BLRX

US09071M2052

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 28/05/2024			Variaz. 5gg	Var. 1 gen.
0,719 ^USD	+4,96%		+15,43%	-54,20%

28/05	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024
24/05	BioLineRx Ltd. annuncia un abstract sui dati dello studio pilota della sperimentazione clinica combinata di Fase 2 che valuta la motixafortide nel tumore al pancreas di prima linea, all'American Society of Clinical Oncology.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	28/05
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	24/05
BioLineRx to Report First Quarter 2024 Results on May 28, 2024	22/05
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification	20/05
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	06/05
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04
BioLineRx Announces $6 Million Registered Direct Offering	02/04
BioLineRx Shares Fall After $6 Million Registered Direct Offering	01/04
BioLineRx : Form 20-F/A (Amendment No. 1	28/03
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	27/03
BioLineRx : Annual Report on Form 20-F FOR 2023	26/03
BioLineRx : Report of Periodic or Interim Report	26/03
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	26/03
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	20/03
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	04/03
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	04/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BioLineRx Ltd. Nasdaq

Azioni

BLRX

US09071M2052

Altre lingue

Filtri